Arcus Group

Arcus Biosciences is a clinical-stage biopharmaceutical company developing differentiated cancer therapies and combination regimens, with a core focus on immuno-oncology and a growing inflammation and autoimmune pipeline. Its lead oncology programs include domvanalimab, a Fc-silent anti-TIGIT antibody; casdatifan, a HIF-2alpha inhibitor for kidney cancer; quemliclustat, a CD73 inhibitor; etrumadenant, a dual adenosine receptor antagonist; and zimberelimab, an anti-PD-1 antibody. The company is advancing multiple late-stage studies in lung, gastrointestinal, pancreatic, and renal cancers, while also building discovery-stage small-molecule and antibody programs in inflammatory disease. Arcus has major strategic collaborations with Gilead Sciences, Taiho, and AstraZeneca, and retains full rights to casdatifan. The company is publicly traded and headquartered in Hayward, California.